JP2017517266A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517266A5 JP2017517266A5 JP2016572447A JP2016572447A JP2017517266A5 JP 2017517266 A5 JP2017517266 A5 JP 2017517266A5 JP 2016572447 A JP2016572447 A JP 2016572447A JP 2016572447 A JP2016572447 A JP 2016572447A JP 2017517266 A5 JP2017517266 A5 JP 2017517266A5
- Authority
- JP
- Japan
- Prior art keywords
- triphosphate
- rna molecule
- sequence
- bioreactor
- ntp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 18
- 238000000034 method Methods 0.000 claims 16
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 239000001226 triphosphate Substances 0.000 claims 14
- 235000011178 triphosphate Nutrition 0.000 claims 14
- 239000002342 ribonucleoside Substances 0.000 claims 10
- -1 ribonucleoside triphosphates Chemical class 0.000 claims 9
- 239000011541 reaction mixture Substances 0.000 claims 8
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 8
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 7
- 238000013518 transcription Methods 0.000 claims 7
- 230000035897 transcription Effects 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 238000005457 optimization Methods 0.000 claims 6
- 239000002777 nucleoside Substances 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 230000002194 synthesizing effect Effects 0.000 claims 3
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 claims 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
- 229920000110 poly(aryl ether sulfone) Polymers 0.000 claims 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 2
- 229920002492 poly(sulfone) Polymers 0.000 claims 2
- 229920002239 polyacrylonitrile Polymers 0.000 claims 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- GKVHYBAWZAYQDO-XVFCMESISA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-(2-oxo-4-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=S)C=C1 GKVHYBAWZAYQDO-XVFCMESISA-N 0.000 claims 1
- KHYOUGAATNYCAZ-XVFCMESISA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=S)NC(=O)C=C1 KHYOUGAATNYCAZ-XVFCMESISA-N 0.000 claims 1
- YIJVOACVHQZMKI-JXOAFFINSA-N [[(2r,3s,4r,5r)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 YIJVOACVHQZMKI-JXOAFFINSA-N 0.000 claims 1
- VEWJOCYCKIZKKV-GBNDHIKLSA-N [[(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1C1=CNC(=O)NC1=O VEWJOCYCKIZKKV-GBNDHIKLSA-N 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091027963 non-coding RNA Proteins 0.000 claims 1
- 102000042567 non-coding RNA Human genes 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000004627 regenerated cellulose Substances 0.000 claims 1
- 239000011342 resin composition Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2014/001577 | 2014-06-10 | ||
| EP2014001577 | 2014-06-10 | ||
| PCT/EP2015/001164 WO2015188933A1 (en) | 2014-06-10 | 2015-06-10 | Methods and means for enhancing rna production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017517266A JP2017517266A (ja) | 2017-06-29 |
| JP2017517266A5 true JP2017517266A5 (enExample) | 2018-05-31 |
| JP6748579B2 JP6748579B2 (ja) | 2020-09-02 |
Family
ID=51033109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572447A Active JP6748579B2 (ja) | 2014-06-10 | 2015-06-10 | Ｒｎａ生成を強化する方法及び手段 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10837039B2 (enExample) |
| EP (2) | EP3521456B1 (enExample) |
| JP (1) | JP6748579B2 (enExample) |
| KR (1) | KR102459599B1 (enExample) |
| CN (1) | CN106661621B (enExample) |
| AU (1) | AU2015273933B2 (enExample) |
| BR (1) | BR112016026980B1 (enExample) |
| CA (1) | CA2945629C (enExample) |
| ES (1) | ES2727776T3 (enExample) |
| MX (1) | MX382298B (enExample) |
| PL (1) | PL3155129T3 (enExample) |
| PT (1) | PT3155129T (enExample) |
| RU (1) | RU2738753C2 (enExample) |
| SG (1) | SG11201608605QA (enExample) |
| WO (1) | WO2015188933A1 (enExample) |
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| CA2859452C (en) | 2012-03-27 | 2021-12-21 | Curevac Gmbh | Artificial nucleic acid molecules for improved protein or peptide expression |
| WO2014127917A1 (en) | 2013-02-22 | 2014-08-28 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| ES2882110T3 (es) | 2013-03-14 | 2021-12-01 | Translate Bio Inc | Métodos y composiciones para administrar anticuerpos codificados con ARNm |
| EP4614148A3 (en) | 2013-03-15 | 2025-12-17 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| CA2915728A1 (en) | 2013-08-21 | 2015-02-26 | Thomas Kramps | Respiratory syncytial virus (rsv) vaccine |
| CN105517569A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 狂犬病疫苗 |
| WO2015024669A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Combination vaccine |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| EP3540060A1 (en) | 2013-12-30 | 2019-09-18 | CureVac AG | Methods for rna analysis |
| AU2014375404C1 (en) | 2013-12-30 | 2020-11-19 | CureVac Manufacturing GmbH | Methods for RNA analysis |
| WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
| ES2754239T3 (es) | 2014-03-12 | 2020-04-16 | Curevac Ag | Combinación de vacunación y agonistas de OX40 |
| CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| US10837039B2 (en) | 2014-06-10 | 2020-11-17 | Curevac Real Estate Gmbh | Methods and means for enhancing RNA production |
| ES2946969T3 (es) | 2014-12-12 | 2023-07-28 | CureVac SE | Moléculas de ácido nucleico artificiales para una expresión proteica mejorada |
| EP3283059B1 (en) | 2015-04-13 | 2024-01-03 | CureVac Manufacturing GmbH | Method for producing rna compositions |
| CN107567497A (zh) | 2015-04-17 | 2018-01-09 | 库瑞瓦格股份公司 | Rna的冻干 |
| WO2016174271A1 (en) | 2015-04-30 | 2016-11-03 | Curevac Ag | Immobilized poly(n)polymerase |
| DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
| JP6893177B2 (ja) | 2015-05-15 | 2021-06-23 | キュアバック アーゲー | 少なくとも１つのｍＲＮＡコンストラクトの投与を含むプライムブーストレジメン（ＰＲＩＭＥ−ＢＯＯＳＴ ＲＥＧＩＭＥＮＳ） |
| SG10201910431RA (en) | 2015-05-20 | 2020-01-30 | Curevac Ag | Dry powder composition comprising long-chain rna |
| WO2016184576A2 (en) | 2015-05-20 | 2016-11-24 | Curevac Ag | Dry powder composition comprising long-chain rna |
| PL4108769T3 (pl) | 2015-05-29 | 2024-02-05 | CureVac Manufacturing GmbH | Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym |
| EP4098743A1 (en) | 2015-05-29 | 2022-12-07 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
| US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
| KR102645398B1 (ko) | 2015-08-28 | 2024-03-07 | 큐어백 에스이 | 신규 인공 핵산 분자 |
| US11225682B2 (en) | 2015-10-12 | 2022-01-18 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
| WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
| JP6949845B2 (ja) | 2015-12-22 | 2021-10-13 | キュアバック アーゲー | Ｒｎａ分子組成物の作製方法 |
| US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| EP4289965A3 (en) | 2016-02-12 | 2024-02-21 | CureVac SE | Method for analyzing rna |
| US11723967B2 (en) | 2016-02-17 | 2023-08-15 | CureVac SE | Zika virus vaccine |
| US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
| KR102369898B1 (ko) | 2016-04-08 | 2022-03-03 | 트랜슬레이트 바이오 인코포레이티드 | 다량체 코딩 핵산 및 그 용도 |
| WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| EP4233898A3 (en) | 2016-05-04 | 2023-11-01 | CureVac SE | Influenza mrna vaccines |
| WO2017191264A1 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Nucleic acid molecules and uses thereof |
| CN109475640B (zh) | 2016-06-09 | 2023-03-10 | 库瑞瓦格欧洲公司 | 核酸被运载物的混合载运体 |
| CN109312313A (zh) | 2016-06-13 | 2019-02-05 | 川斯勒佰尔公司 | 用于治疗鸟氨酸转氨甲酰酶缺乏症的信使rna疗法 |
| JP6983455B2 (ja) * | 2016-09-14 | 2021-12-17 | モデルナティーエックス， インコーポレイテッド | 高純度ｒｎａ組成物及びその調製のための方法 |
| WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| EP3808380A1 (en) | 2016-12-08 | 2021-04-21 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
| US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
| WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
| WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| US11464847B2 (en) | 2016-12-23 | 2022-10-11 | Curevac Ag | Lassa virus vaccine |
| CN119351474A (zh) | 2017-02-22 | 2025-01-24 | 克里斯珀医疗股份公司 | 用于基因编辑的组合物和方法 |
| WO2018157153A1 (en) * | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Large scale synthesis of messenger rna |
| US20200085944A1 (en) | 2017-03-17 | 2020-03-19 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
| CN110914433A (zh) | 2017-03-24 | 2020-03-24 | 库尔维科公司 | 编码crispr相关蛋白质的核酸及其用途 |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| US12474242B2 (en) * | 2017-04-21 | 2025-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Exposome tracker for environmental health |
| WO2018195404A1 (en) * | 2017-04-21 | 2018-10-25 | The Board Of The Trustees Of The Leland Stanford Junior University | Ultra-sensitive and universal species detection pipeline for next generation sequencing data |
| US12297489B2 (en) | 2017-05-17 | 2025-05-13 | CureVac Manufacturing GmbH | Method for determining at least one quality parameter of an RNA sample |
| BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
| US11001868B2 (en) * | 2017-08-11 | 2021-05-11 | Global Life Sciences Solutions Operations UK Ltd | Cell-free protein expression using double-stranded concatameric DNA |
| EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
| US11692002B2 (en) | 2017-11-08 | 2023-07-04 | CureVac SE | RNA sequence adaptation |
| EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
| US11167043B2 (en) | 2017-12-20 | 2021-11-09 | Translate Bio, Inc. | Composition and methods for treatment of ornithine transcarbamylase deficiency |
| CN111511928A (zh) | 2017-12-21 | 2020-08-07 | 库瑞瓦格股份公司 | 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法 |
| WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| DE202019006199U1 (de) | 2018-04-17 | 2026-01-12 | CureVac SE | Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung |
| US20210260178A1 (en) | 2018-06-27 | 2021-08-26 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
| WO2020002598A1 (en) * | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
| TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| US12492425B2 (en) | 2018-12-21 | 2025-12-09 | CureVac SE | Methods for RNA analysis |
| CN113453707A (zh) | 2018-12-21 | 2021-09-28 | 库瑞瓦格股份公司 | 用于疟疾疫苗的rna |
| CN113874502A (zh) * | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12359248B2 (en) | 2019-04-24 | 2025-07-15 | University Of Massachusetts | Enzymatic methods to generate high yields of sequence specific RNAs with extreme precision |
| US11578348B2 (en) * | 2019-04-24 | 2023-02-14 | The University Of Massachusetts | Enzymatic methods to generate high yields of sequence specific rna with extreme precision |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| JP2022544412A (ja) * | 2019-08-14 | 2022-10-18 | キュアバック アーゲー | 免疫賦活特性が減少したｒｎａ組み合わせおよび組成物 |
| CN114901360A (zh) | 2019-12-20 | 2022-08-12 | 库瑞瓦格股份公司 | 用于递送核酸的新型脂质纳米颗粒 |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| EP3886897A1 (en) | 2020-02-04 | 2021-10-06 | CureVac AG | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| MX2022010117A (es) * | 2020-02-18 | 2022-11-14 | Translate Bio Inc | Procesos mejorados para la transcripción in vitro del arn mensajero. |
| EP4136248A4 (en) * | 2020-04-16 | 2025-07-23 | Natures Toolbox Inc | IN VITRO MANUFACTURE AND PURIFICATION OF THERAPEUTIC MRNA |
| GB2597436B (en) * | 2020-05-12 | 2025-03-26 | Makatsoris Charalampos | A method and apparatus for RNA synthesis |
| CN120099118A (zh) * | 2020-05-12 | 2025-06-06 | 查拉拉姆波斯·马卡里奥斯 | 用于合成基于rna的治疗剂的方法和模块化设备 |
| CN116322758A (zh) | 2020-05-29 | 2023-06-23 | 库尔维科欧洲股份公司 | 基于核酸的组合疫苗 |
| EP4172194A1 (en) | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
| CA3170743A1 (en) | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
| US20240246056A1 (en) | 2020-09-01 | 2024-07-25 | CureVac RNA Printer GmbH | Manufacturing device for a pharmaceutical product |
| EP4208549A4 (en) | 2020-09-04 | 2025-04-16 | Verve Therapeutics, Inc. | Compositions and methods for capping RNAs |
| JP2023545503A (ja) * | 2020-10-15 | 2023-10-30 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの大規模合成 |
| CA3195982A1 (en) | 2020-10-23 | 2022-04-28 | Spindle Biotech Inc. | Compositions and methods for rna synthesis |
| JP7641487B2 (ja) | 2020-11-27 | 2025-03-07 | キュアバック マニュファクチャリング ゲーエムベーハー | キャピラリーポリメラーゼ連鎖反応によってｄｎａ産物を調製するためのデバイス |
| JP2023552468A (ja) * | 2020-12-09 | 2023-12-15 | ビオンテック・ソシエタス・エウロパエア | Ｒｎａの製造 |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| CN114717229B (zh) * | 2021-01-05 | 2024-09-10 | 麦塞拿治疗(香港)有限公司 | 治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子 |
| CN114717230B (zh) * | 2021-01-05 | 2024-09-03 | 麦塞拿治疗(香港)有限公司 | 成纤维细胞生长因子mRNA的无细胞和无载体体外RNA转录方法和核酸分子 |
| WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
| EP4087938A2 (en) | 2021-01-27 | 2022-11-16 | CureVac AG | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| MX2023011400A (es) | 2021-03-26 | 2023-10-09 | Glaxosmithkline Biologicals Sa | Composiciones inmunogenicas. |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| EP4351777A4 (en) * | 2021-06-07 | 2025-04-16 | The University of Massachusetts | Apparatus and method for the continuous production of RNA |
| US20240167068A1 (en) * | 2021-06-30 | 2024-05-23 | Etherna Immunotherapies Nv | Method for rna manufacturing |
| TWI814499B (zh) * | 2021-07-22 | 2023-09-01 | 中央研究院 | 用以連續製備及分析ｒｎａ的裝置以及利用該裝置來合成ｒｎａ的方法 |
| WO2023007019A1 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
| EP4392140A1 (en) * | 2021-08-24 | 2024-07-03 | BioNTech SE | In vitro transcription technologies |
| US20250027108A1 (en) | 2021-10-29 | 2025-01-23 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| US12037616B2 (en) | 2022-03-01 | 2024-07-16 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions |
| TW202403046A (zh) | 2022-03-21 | 2024-01-16 | 瑞士商Ｃｒｉｓｐｒ治療公司 | 用於治療脂蛋白相關的疾病之方法及組成物 |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| CA3267272A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | FLU VIRUS VACCINES |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| EP4658664A1 (en) | 2023-01-31 | 2025-12-10 | CureVac SE | Cap analogs with 5'-terminal acyclic guanosine derivative |
| EP4658239A1 (en) | 2023-02-03 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| WO2024223728A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| EP4701657A1 (en) | 2023-04-27 | 2026-03-04 | GlaxoSmithKline Biologicals S.A. | Influenza virus vaccines |
| CN116554995A (zh) * | 2023-05-11 | 2023-08-08 | 北京沃森创新生物技术有限公司 | mRNA连续体外转录反应系统和连续转录方法 |
| WO2024235451A1 (en) | 2023-05-16 | 2024-11-21 | CureVac RNA Printer GmbH | Improved rna in vitro transcription using dna beads |
| WO2024245907A1 (en) | 2023-05-26 | 2024-12-05 | CureVac SE | Cancer antigens |
| US20250027087A1 (en) | 2023-07-21 | 2025-01-23 | Crispr Therapeutics Ag | Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene |
| WO2025035110A1 (en) * | 2023-08-10 | 2025-02-13 | Linearx, Inc. | Compositions and methods for in vitro transcription |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| GB202317972D0 (en) * | 2023-11-24 | 2024-01-10 | Univ Sheffield | In vitro transcription method |
| GB2637389A (en) * | 2023-11-24 | 2025-07-23 | Univ Sheffield | In vitro transcription method |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| EP4574990A1 (en) * | 2023-12-22 | 2025-06-25 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Methods and systems for producing peptides and proteins |
| US20250269059A1 (en) | 2024-02-27 | 2025-08-28 | Crispr Therapeutics Ag | Rt editing compositions and methods |
| WO2025186726A1 (en) | 2024-03-05 | 2025-09-12 | Crispr Therapeutics Ag | Modulating expression of agt (angiotensinogen) gene |
| US12492420B2 (en) | 2024-03-29 | 2025-12-09 | New England Biolabs, Inc. | Compositions, kits, and methods for in vitro transcription |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| WO2025217602A1 (en) * | 2024-04-12 | 2025-10-16 | Sartorius Bioanalytical Instruments, Inc. | Systems and methods for rna transcription |
| WO2026015876A1 (en) * | 2024-07-12 | 2026-01-15 | Arcturus Therapeutics, Inc. | Improved methods for in vitro transcription |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256555A (en) | 1991-12-20 | 1993-10-26 | Ambion, Inc. | Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions |
| US5434079A (en) | 1993-02-12 | 1995-07-18 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and process for continuous in vitro synthesis of proteins |
| WO1995008626A1 (en) * | 1993-09-20 | 1995-03-30 | The Regents Of The University Of Colorado | Strategy for the production of rna from immobilized templates |
| EP1903054A3 (de) | 2001-06-05 | 2008-07-23 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| DE10240868A1 (de) | 2002-09-04 | 2004-03-18 | Artus Gesellschaft für molekularbiologische Diagnostik und Entwicklung mbH | Verbesserte Verfahren zur Synthese von Nukleinsäuren |
| WO2005003395A1 (en) | 2003-07-02 | 2005-01-13 | Caliper Life Sciences, Inc. | Method for amplifying and detecting nucleic acids in microfluidic devices under continuous and non-continuous flow conditions |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| US20050287539A1 (en) * | 2004-06-29 | 2005-12-29 | Emmanuel Labourier | Methods and compositions for preparing capped RNA |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| HUE043492T2 (hu) | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
| WO2008016473A2 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
| DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| EP2167523B1 (en) | 2007-06-19 | 2014-07-23 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| CN101932707B (zh) | 2008-01-31 | 2013-08-21 | 库瑞瓦格有限责任公司 | 作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物 |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| US20120208242A1 (en) | 2009-10-21 | 2012-08-16 | Riboxx Gmbh | Method and RNA Reactor for Exponential Amplification of RNA |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| US8968746B2 (en) | 2010-07-30 | 2015-03-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2012122413A1 (en) | 2011-03-08 | 2012-09-13 | University Of Maryland Baltimore County | Microscale bioprocessing system and method for protein manufacturing |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| US9862926B2 (en) * | 2011-06-27 | 2018-01-09 | Cellscript, Llc. | Inhibition of innate immune response |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US8969545B2 (en) | 2011-10-18 | 2015-03-03 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| CA2859452C (en) | 2012-03-27 | 2021-12-21 | Curevac Gmbh | Artificial nucleic acid molecules for improved protein or peptide expression |
| MX357803B (es) | 2012-03-27 | 2018-07-24 | Curevac Ag | Moléculas de ácido nucleico artificiales. |
| SG11201405545XA (en) | 2012-03-27 | 2014-11-27 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| WO2013151663A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| ES2719598T3 (es) | 2012-05-25 | 2019-07-11 | Curevac Ag | Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables) |
| WO2014127917A1 (en) | 2013-02-22 | 2014-08-28 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| WO2015024669A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Combination vaccine |
| CN105517566A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 用于治疗前列腺癌的组合物和疫苗 |
| CA2915728A1 (en) | 2013-08-21 | 2015-02-26 | Thomas Kramps | Respiratory syncytial virus (rsv) vaccine |
| AU2014310933B2 (en) | 2013-08-21 | 2020-05-14 | CureVac SE | Method for increasing expression of RNA-encoded proteins |
| JP6678582B2 (ja) | 2013-08-21 | 2020-04-08 | キュアバック アーゲー | 肺癌処置のための組成物およびワクチン、組み合わせ、キット |
| CN105517569A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 狂犬病疫苗 |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| AU2014375404C1 (en) | 2013-12-30 | 2020-11-19 | CureVac Manufacturing GmbH | Methods for RNA analysis |
| ES2754239T3 (es) | 2014-03-12 | 2020-04-16 | Curevac Ag | Combinación de vacunación y agonistas de OX40 |
| CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| US10837039B2 (en) | 2014-06-10 | 2020-11-17 | Curevac Real Estate Gmbh | Methods and means for enhancing RNA production |
| ES2946969T3 (es) | 2014-12-12 | 2023-07-28 | CureVac SE | Moléculas de ácido nucleico artificiales para una expresión proteica mejorada |
| WO2016097065A1 (en) | 2014-12-16 | 2016-06-23 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
| JP6907116B2 (ja) | 2014-12-30 | 2021-07-21 | キュアバック アーゲー | 人工核酸分子 |
| EP3173092B1 (en) | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
| DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
-
2015
- 2015-06-10 US US15/317,579 patent/US10837039B2/en active Active
- 2015-06-10 AU AU2015273933A patent/AU2015273933B2/en active Active
- 2015-06-10 WO PCT/EP2015/001164 patent/WO2015188933A1/en not_active Ceased
- 2015-06-10 SG SG11201608605QA patent/SG11201608605QA/en unknown
- 2015-06-10 MX MX2016016170A patent/MX382298B/es unknown
- 2015-06-10 RU RU2017100044A patent/RU2738753C2/ru active
- 2015-06-10 PL PL15738263T patent/PL3155129T3/pl unknown
- 2015-06-10 CA CA2945629A patent/CA2945629C/en active Active
- 2015-06-10 JP JP2016572447A patent/JP6748579B2/ja active Active
- 2015-06-10 ES ES15738263T patent/ES2727776T3/es active Active
- 2015-06-10 EP EP18001012.6A patent/EP3521456B1/en not_active Revoked
- 2015-06-10 CN CN201580031536.2A patent/CN106661621B/zh active Active
- 2015-06-10 BR BR112016026980-2A patent/BR112016026980B1/pt not_active IP Right Cessation
- 2015-06-10 KR KR1020167035028A patent/KR102459599B1/ko active Active
- 2015-06-10 PT PT15738263T patent/PT3155129T/pt unknown
- 2015-06-10 EP EP15738263.1A patent/EP3155129B1/en active Active
-
2020
- 2020-10-15 US US17/071,279 patent/US20210040526A1/en not_active Abandoned
-
2024
- 2024-02-20 US US18/582,620 patent/US20240218412A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017100044A (ru) | Способы и средства повышения продуктивности рнк | |
| JP2016530294A5 (enExample) | ||
| JP2019533476A5 (enExample) | ||
| ES2827307T3 (es) | Métodos y composiciones para la síntesis de ADNc y la elaboración del perfil del transcriptoma de células individuales utilizando una reacción de cambio de plantilla | |
| RU2016107198A (ru) | Аналоги нуклеотидов | |
| WO2015031691A1 (en) | Massively parallel single cell analysis | |
| JP2016535983A5 (enExample) | ||
| US20220195424A1 (en) | Chemical Capping for Template Switching | |
| JP2021520815A5 (enExample) | ||
| RU2019137083A (ru) | Линкеры в виде короткой боковой ручки для нуклеотидов в областях применения секвенирования | |
| WO2017058810A3 (en) | Polymerase compositions and kits, and methods of using and making the same | |
| BR112021021491A2 (pt) | Método de amplificação de mrnas e para a preparação de bibliotecas de mrna de comprimento total | |
| Majumdar et al. | Increasing the functional density of threose nucleic acid | |
| Zhang et al. | Synthesis of threose nucleic acid (TNA) triphosphates and oligonucleotides by polymerase‐mediated primer extension | |
| Kaur et al. | Production of long linear DNA substrates with site-specific chemical lesions for single-molecule replisome studies | |
| EP4004202A1 (en) | Methods for tagging and encoding of pre-existing compound libraries | |
| JP2013526273A5 (enExample) | ||
| BR112017008508A2 (pt) | método para purificar oses sem ajustar o ph | |
| Chemama et al. | Flexible Nucleic Acids (FNAs) as Informational Molecules: Enzymatic Polymerization of fNTPs on DNA Templates and Nonenzymatic Oligomerization of RNA on FNA Templates | |
| Liu et al. | An H-phosphonate strategy for the synthesis of aciclovir 5′-triphosphate | |
| WO2024137765A1 (en) | Transition-metal catalyst compositions and methods for sequencing by synthesis | |
| Li et al. | A Novel Synthesis of Acyclovir Polyphosphates via Acyclovir Phosphoropiperidate Intermediate | |
| KR20250001916A (ko) | C(5)-할로겐화 피리미딘 리보뉴클레오타이드가 결합된 mRNA 및 이를 이용하여 단백질의 발현을 높이는 방법 | |
| WO2022175685A1 (en) | Modified guanines | |
| Wei et al. | Towards Co-evolution of Membrane Transport and Metabolism |